A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...
MarketBeat on MSN
2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025
Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...
This story is part of a series on the current progression in Regenerative Medicine. In 1999, I defined regenerative medicine as the collection of interventions that restore tissues and organs damaged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback